Abivax SA American Share...
(ABVX)
undefined
undefined%
At close: undefined
7.40
3.50%
Pre-market Dec 16, 2024, 07:01 AM EST
Company Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Abivax SA American Shares
| Country | United States |
| IPO Date | Oct 20, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 62 |
| CEO | Marc M. P. de Garidel M.B.A. |
Contact Details
Address: 7-11 boulevard Haussmann Paris, United States | |
| Website | https://www.abivax.com |
Stock Details
| Ticker Symbol | ABVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001956827 |
| CUSIP Number | n/a |
| ISIN Number | US00370M1036 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marc M. P. de Garidel M.B.A. | Chief Executive Officer & Director |
| Didier Blondel | EVice President, Chief Financial Officer & Board Secretary |
| Ana Sharma M.P.H. | Vice President & Global Head of Quality |
| Didier Scherrer Ph.D. | Chief Scientific Officer |
| Dr. Philippe Pouletty M.D., Ph.D. | Founder & Director |
| Hema Keshava | Senior Vice President of Finance |
| Ida Hatoum | Chief People & Compliance Officer |
| Jerome Denis Ph.D. | Executive Vice President of Process Development & Manufacturing |
| Patrick Malloy | Senior Vice President of Investor Relations |
| Pierre Courteille M.B.A. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | 6-K | Filing |
| Nov 19, 2024 | F-3 | Filing |
| Nov 14, 2024 | 6-K | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 03, 2024 | 6-K | Filing |
| Oct 03, 2024 | 6-K | Filing |
| Sep 26, 2024 | 6-K | Filing |
| Sep 25, 2024 | 6-K | Filing |
| Sep 09, 2024 | 6-K | Filing |
| Sep 09, 2024 | 6-K | Filing |